Recommended Dosing Guide for Eporatio® (epoetin theta) in Symptomatic Anaemia in Cancer Patients with Non-myeloid Malignancies Receiving Chemotherapy.¹

**Initial Dose**

Initiate Eporatio® by SC route when Hb ≤ 10 g/dl Symptomatic anaemia.

The recommended initial dose is 20,000 IU, independent of bodyweight, given once-weekly.

**First Evaluation (4 weeks)**

If, after 4 weeks of therapy, the haemoglobin value has increased by at least 1 g/dl (0.62 mmol/l), the current dose should be continued.

If the haemoglobin value has not increased by at least 1 g/dl (0.62 mmol/l) a doubling of the weekly dose to 40,000 IU should be considered.

**Second Evaluation (8 weeks)**

If, after 4 weeks of therapy, the haemoglobin value has increased by at least 1 g/dl (0.62 mmol/l), the current dose should be continued.

If, after an additional 4 weeks of therapy, the haemoglobin increase is still insufficient an increase of the weekly dose to 60,000 IU should be considered.

**Third Evaluation (12 weeks)**

If, after 12 weeks of therapy, the haemoglobin value has not increased by at least 1 g/dl (0.62 mmol/l), response is unlikely and treatment should be discontinued.

**Ongoing Evaluation**

Continue treatment until the Hb target is reached (range ≥ 10g/dl to ≤ 12g/dl) Therapy should be continued up to 4 weeks after the end of chemotherapy.

If the rise in haemoglobin is greater than 2 g/dl (1.24 mmol/l) in 4 weeks or the haemoglobin level exceeds 12 g/dl (7.45 mmol/l), the dose should be reduced by 25 to 50%. Treatment with epoetin theta should be temporarily discontinued if haemoglobin levels exceed 13 g/dl (8.07 mmol/l). Therapy should be reinitiated at approximately 25% lower than the previous dose after haemoglobin levels fall to 12 g/dl (7.45 mmol/l) or below. Patients should be monitored closely to ensure that the lowest approved dose of epoetin theta is used to provide adequate control of the symptoms of anaemia.

Eporatio® is indicated for the treatment of symptomatic anaemia in adult patients with non-myeloid malignancies receiving chemotherapy.

(SC) Subcutaneously (HB) Haemoglobin (IU) International units

The maximum dose of Eporatio® should not exceed 60,000 IU per week.

**Teva Point of Care Nurse service:** Tel: 01 499 2674

---

¹ For full prescribing information, refer to Summary of Product Characteristics.